An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer

Gynecologic Oncology

Volumn 113, Issue 1, 2009, Pages 63-67

  Berry, Emily ^a   Matthews, Kellie S ^c   Singh, Diljeet K ^b   Buttin, Barbara M ^b   Lurain, John R ^b   Alvarez, Ronald D ^c   Schink, Julian ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antineoplastic combined chemotherapy; Cisplatin; Intraperitoneal chemotherapy; Outpatient; Ovarian adenocarcinoma; Paclitaxel

Indexed keywords

AMIFOSTINE; APREPITANT; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; LORAZEPAM; PACLITAXEL; PALONOSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CATHETER INFECTION; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; DIARRHEA; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INTESTINE PERFORATION; LUNG EMBOLISM; MEDICAL RECORD REVIEW; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT; OUTPATIENT CARE; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN TOXICITY; THROMBOCYTOPENIA; TINNITUS; VAGINA DISEASE;

ADENOCARCINOMA; ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM STAGING; OUTPATIENTS; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PILOT PROJECTS; RETROSPECTIVE STUDIES;

EID: 62549086510     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.12.035     Document Type: Article

References (18)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer Statistics, 2007. CA Cancer J. Clin. 57 (2007) 43-66
2. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
3. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
4. Jones R.B., Myers C.E., Guarino A.M., Dedrick R.L., Hubbard S.M., and DeVita V.T. High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother. Pharmacol. 1 (1978) 161-166
5. Dedrick R.L., Myers C.E., Bungay P.M., and DeVita Jr. V.T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62 (1978) 1-11
6. Dedrick R.L., and Flessner M.F. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J. Natl. Cancer Inst. 89 (1997) 480-487
7. Markman M., Rowinsky E., Hakes T., Reichman B., Jones W., Lewis Jr. J.L., et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J. Clin. Oncol. 10 (1992) 1485-1491
8. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
9. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24 (2006) 3187-3205
10. Hesketh P.J., Grunberg S.M., Gralla R.J., Warr D.G., Roila F., de Wit R., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J. Clin. Oncol. 21 (2003) 4112-4119
11. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004) 1682-1691
12. Kemp G., Rose P., Lurain J., Berman M., Manetta A., Roullet B., et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 14 (1996) 2101-2112
13. Fujiwara K., Suzuki S., Ishikawa H., Oda T., Aotani E., and Kohno I. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int. J. Gynecol. Cancer 15 (2005) 426-431
14. Davidson S.A., Rubin S.C., Markman M., Jones W.B., Hakes T.B., Reichman B., et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol. Oncol. 41 (1991) 101-106
15. Makhija S., Leitao M., Sabbatini P., Bellin N., Almadrones L., Leon L., et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol. Oncol. 81 (2001) 77-81
16. Black D., Levine D.A., Nicoll L., Chou J.F., Iasonos A., Brown C.L., et al. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol. Oncol. 109 (2008) 39-42
17. Walker J.L., Armstrong D.K., Huang H.Q., Fowler J., Webster K., Burger R.A., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol. Oncol. 100 (2006) 27-32
18. Landrum L.M., Gold M.A., Moore K.N., Myers T.K., McMeekin D.S., and Walker J.L. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol. Oncol. 108 (2008) 342-347